Aktiia secures $42 million in Series B funding round; rebrands to Hilo

Aktiia, a blood pressure intelligence platform, has announced an oversubscribed $40 million Series B funding round co-led by Earlybird Health and Wellington Partners, with new investors Kfund and NaturalX Health Ventures, and participation from existing investors redalpine, Khosla Ventures, Molten Ventures, Translink Capital and Verve Ventures. The investment, which has brought the total financing to date to $98 million, will accelerate the company’s mission to manage the world’s blood pressure.

Alongside this funding, Aktiia is introducing its new brand identity: Hilo - a rebrand that reflects its global ambition to make cuffless, clinically validated blood pressure monitoring accessible worldwide, supporting its vision of healthier blood pressure for all.

The latest investment builds on a period of significant momentum for the company during which it has achieved several major milestones, including securing CE marking for its innovative phone camera blood pressure monitoring technology, successfully launching in Canada, and completing a pivotal clinical trial ahead of its U.S. FDA application submission. This Series B funding will fuel continued product innovation, expansion into new markets and the build out of its blood pressure intelligence platform to support enterprise use cases. 

With more than 120,000 devices sold, Hilo has already established itself as a stand-out in the health tech space. The company has developed a foundation model - a type of advanced AI - specifically designed for blood pressure monitoring. It has been trained on tens of billions of optical signals from real-world users and further refined with hundreds of millions of calibration points, strengthening its position as a leader in the emerging cuffless blood pressure monitoring (CBPM) category.

The transition from Aktiia to Hilo marks an important milestone in the company’s journey, aligning with its vision of making blood pressure monitoring universally accessible and effortless. While the name and branding have changed, Hilo remains committed to providing the same trusted technology and clinically validated monitoring reports that have been central to the company’s platform and proposition. 

Raghav “Rags” Gupta, CEO of Hilo, commented: “This funding round is a testament to the confidence our investors have in Hilo’s groundbreaking technology and our mission to manage the world’s blood pressure via more frequent, convenient and accurate measurements. With billions worldwide suffering from hypertension, only 20% of whom are in control of their blood pressure, the need for innovative, accessible blood pressure monitoring solutions has never been greater. Our rebrand to Hilo represents more than just a name change, it’s a commitment to empowering users around the world with smarter tools to optimise their health. We are grateful to early Aktiia customers for their support and to our investors, new and existing, for their faith.”